{"organizations": [], "uuid": "38653b77d465f679c637c5045b92083c9ec6089a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-gensight-announces-publication-of/brief-gensight-announces-publication-of-positive-data-from-phase-i-ii-trial-of-gs010-idUSFWN1Q90J6", "country": "US", "domain_rank": 408, "title": "BRIEF-Gensight Announces Publication Of Positive Data From Phase I/II Trial Of Gs010", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.174, "site_type": "news", "published": "2018-02-20T14:38:00.000+02:00", "replies_count": 0, "uuid": "38653b77d465f679c637c5045b92083c9ec6089a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-gensight-announces-publication-of/brief-gensight-announces-publication-of-positive-data-from-phase-i-ii-trial-of-gs010-idUSFWN1Q90J6", "ord_in_thread": 0, "title": "BRIEF-Gensight Announces Publication Of Positive Data From Phase I/II Trial Of Gs010", "locations": [], "entities": {"persons": [{"name": "gensight", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - GENSIGHT BIOLOGICS SA:\n* GENSIGHT BIOLOGICS ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE I/II TRIAL AND LONG-TERM FOLLOW-UP OF GS010 IN OPHTHALMOLOGY, THE JOURNAL OF THE AMERICAN ACADEMY OF OPHTHALMOLOGY\n* GS010 CONFIRMED AS SAFE AND WELL TOLERATED 2 YEARS AFTER A SINGLE UNILATERAL INTRAVITREAL INJECTION\n* SUSTAINED IMPROVEMENT OF VISUAL ACUITY AT 2 YEARS OF FOLLOW-UP IN LHON SUBJECTS WITH LESS THAN 2 YEARS OF VISUAL LOSS PRIOR TO TREATMENT\n* GS010 (RAAV2/2-ND4) IS SAFE AND WELL TOLERATED 2 YEARS AFTER A SINGLE UNILATERAL INTRAVITREAL ADMINISTRATION. Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T14:38:00.000+02:00", "crawled": "2018-02-21T21:21:17.089+02:00", "highlightTitle": ""}